RxDoctor Payments Data

Kleper de Almeida, MD

Infectious Disease · Atlantis, FLNPI 1285600825

Payments from drug & device makers

$11,262in general payments, 2019–2025

Across 33 payments — averaging $341.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Karyopharm Therapeutics Inc.$11K
  • AbbVie$147
  • Insmed, Inc.$90
  • Merck$75
  • Amgen$60
  • Lilly USA, LLC$38
  • plus $152 from 8 others

What the payments were for

  • Food & beverage$562100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$11,262 in reported general payments places this provider in the 80th percentile of 669 infectious disease providers in Florida.

See all infectious disease providers in Florida

Medicare billing

Part B allowed, 2024
$87,764
Medicare patients
200
Services billed
3,342

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide70$82,402
EliquisApixaban63$65,651
BiktarvyBictegrav/Emtricit/Tenofov Ala12$45,918
FarxigaDapagliflozin Propanediol29$21,192
XareltoRivaroxaban28$19,501
JardianceEmpagliflozin16$17,893
RybelsusSemaglutide13$16,216
Repatha SyringeEvolocumab14$7,708
PaxlovidNirmatrelvir/Ritonavir24$2,881
Atorvastatin Calcium178$2,541
Ezetimibe45$1,671
Estradiol13$1,049
Valsartan35$997
Amlodipine-ValsartanAmlodipine Besylate/Valsartan23$918
Tamsulosin Hcl27$896

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$38$82,40270 claims
PfizerEliquis, Paxlovid$25$68,53287 claims
GileadBiktarvy$30$45,91812 claims
Johnson & JohnsonXarelto$12$19,50128 claims
Novo NordiskRybelsus$25$16,21613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 669 infectious disease providers in Florida.

Other infectious disease in Atlantis

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →